Integrated Wealth Concepts LLC Sells 60 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Integrated Wealth Concepts LLC decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,170 shares of the medical research company’s stock after selling 60 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Charles River Laboratories International were worth $230,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Oregon Public Employees Retirement Fund grew its position in Charles River Laboratories International by 1.0% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock valued at $914,000 after acquiring an additional 45 shares during the last quarter. Empirical Finance LLC grew its holdings in shares of Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after purchasing an additional 53 shares during the last quarter. American Trust grew its holdings in shares of Charles River Laboratories International by 5.9% in the second quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after purchasing an additional 54 shares during the last quarter. Tortoise Investment Management LLC increased its stake in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after buying an additional 57 shares during the period. Finally, OLD National Bancorp IN lifted its holdings in Charles River Laboratories International by 3.1% during the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after buying an additional 59 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CRL has been the topic of a number of research reports. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. TD Cowen raised their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. Finally, UBS Group upped their price objective on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $214.00.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Trading Down 2.0 %

NYSE CRL opened at $190.45 on Friday. Charles River Laboratories International, Inc. has a 52 week low of $176.48 and a 52 week high of $275.00. The company has a 50 day moving average price of $194.35 and a 200 day moving average price of $203.10. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $9.74 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.72 earnings per share. As a group, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).